Seeking Alpha·Sep 16, 2026
Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptShoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Shoulder Innovations is successfully capturing market share with its InSet technology, evidenced by a 64.9% year-over-year revenue growth in 2026Q1. However, the company's aggressive commercialization strategy has resulted in a -53.7% operating margin and a ra...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.46-0.3% vs -$0.46 | $17M+3.7% vs $17M |
Q2 2026 May 13, 2026 | -$0.41+6.8% vs -$0.44 | $17M+14.9% vs $15M |
Q2 2026 Mar 10, 2026 | -$0.38+9.5% vs -$0.42 | $14M+12.7% vs $13M |
Q4 2025 Nov 11, 2025 | -$0.48-29.7% vs -$0.37 | $12M+19.1% vs $10M |
Shoulder Innovations, Inc. (SI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity.
GRAND RAPIDS, Mich., Sept. 9, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has entered into an exclusive collaboration with ALM Ortho, Inc. ("ALM Ortho"), a leader in additive manufacturing of titanium orthopedic implants, to introduce a bespoke implant for the treatment of severe shoulder deformity and other highly complex revision cases, circumstances for which no adequate solution currently exists.
GRAND RAPIDS, Mich., Sept. 8, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that it has entered into a settlement agreement with Catalyst OrthoScience Inc. ("Catalyst") to resolve all outstanding patent litigation between the two companies.
Benchmark SI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Shoulder Innovations, Inc. (SI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.37 | $360.22M | -8.86 | 49.63% | -85.29% | -80.52% | — | |
| $73.96 | $9.97B | 18.87 | 16.65% | 17.03% | 11.59% | — | |
| $10.03 | $1.54B | -10.45 | 24.95% | -13.5% | -818.99% | — | |
| $0.38 | $52.6M | 12.50 | 14.21% | -10.17% | -23.45% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $90.88 | $17.58B | 25.60 | 7.2% | 9.48% | 6.36% | — |
Shoulder Innovations, Inc. (SI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Shoulder Innovations, Inc. (SI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 6, 2026·SEC
Jun 29, 2026·SEC
Mar 10, 2026·SEC
Get notified when SI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Shoulder Innovations, Inc. (SI) stock FAQ — growth, dividends, profitability & financials explained
Shoulder Innovations, Inc. (SI) reported $60.1M in revenue for fiscal year 2025. This represents a 212% increase from $19.3M in 2023.
Shoulder Innovations, Inc. (SI) grew revenue by 49.6% over the past year. This is strong growth.
Shoulder Innovations, Inc. (SI) reported a net loss of $35.0M for fiscal year 2025.
Shoulder Innovations, Inc. (SI) has a return on equity (ROE) of -80.5%. Negative ROE indicates the company is unprofitable.
Shoulder Innovations, Inc. (SI) had negative free cash flow of $47.1M in fiscal year 2025, likely due to heavy capital investments.
